Neue Therapien für die axiale SpA? − Andere Biologika als TNF-Blocker

1 Braun J., van den Berg R., Baraliakos X. et al.: 2010 update oft he ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70: 896–904
2 Chen J., Liu C.: Sulfaslazine for ankylosing spondylitis. Conchrane Database of Syst Rev 2005; 2; CD004800
3 Chen J, Liu C. Methotrexate for ankylosing spondylitis. Cochrane Database of Syst Rev 2004; 3; CD004524
4 van der Heijde D., Sieper J., Maksymowych W.P. et al.: 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011 Jun; 70 (6): 905–8
5 Sieper J., Porter-Brown B., Thompson L. et al.: Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis – results of randomised, placebo-controlled trials. Ann Rheum Dis 2014; 73: 95–100
6 Sieper J., Braun J., Kay J. et al.: Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis 2014; doi:10.1136/annrheumdis-2013-204963
7 Song I.C.H., Heldmann F., Rudwaleit M. et al.: Different response to rituximab in TNF-blocker-naive patients with active ankylosing spondylitis and patients in whom TNF-blockers have failed. Arthritis Rheumatol 2010; 62: 1290–97
8 Wendling D., Dougados M., Berenbaum F. et al.: A nationwide series: data from the AIR Registry oft he French Society of Rheumatology. J Rheumatol 2012; 39: 2327–31
9 Song I.C.H., Heldmann F., Rudwaleit M. et al.: Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 2011; 70: 1108–10
10 Poddubnyy D., Hermann K.G., Callhoff J. et al.: Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis 2014; 73: 817–23
11 Beaten D., Baraliakos X., Braun J. et al.: Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 2014 Nov 23; 382: 1705–13
12 Pathan E., Abraham S., van Rossen E. et al.: Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis 2013; 72: 1475–80